

U.S. Serial No. 09/759,112  
Amendment dated December 29, 2003  
Response to Office Action of September 25, 2003

**Amendments to the Claims:**

This listing of claims replaces all prior versions of claims in the application.

**Listing of Claims:**

Claim 1 (currently amended): An isolated polynucleotide that contains a nucleotide sequence encoding at least one complementarity-determining region (CDR) or framework-determining region (FR) of an anti-idiotypic antibody that binds to human or primate anti-HIV antibodies, wherein said nucleotide sequence encodes the amino acid sequence shown in SEQ ID NO: 7 or SEQ ID NO: 24.

Claim 2 (previously presented): The polynucleotide of claim 1, wherein the anti-idiotypic antibody is monoclonal antibody 1F7 produced by hybridoma ATCC Accession No. HB 11286.

Claim 3 (previously presented): The polynucleotide of claim 1, wherein said CDR is a variable heavy (VH) or variable light (VL) chain CDR of monoclonal antibody 1F7.

Claims 4-5 (canceled)

U.S. Serial No. 09/759,112  
Amendment dated December 29, 2003  
Response to Office Action of September 25, 2003

Claim 6 (previously presented): The polynucleotide of claim 1,  
wherein said FR is a variable heavy (VH) or variable light (VL)  
chain FR of monoclonal antibody 1F7.

Claims 7-9 (canceled)

Claim 10 (previously presented): The polynucleotide of claim 1,  
wherein said nucleotide sequence is shown in SEQ ID NO: 5 or SEQ  
ID NO: 22.

Claim 11 (previously presented): The polynucleotide of claim 1,  
wherein said nucleotide sequence is operably linked to a human  
immunoglobulin constant region nucleotide sequence.

Claim 12 (currently amended): A vector comprising a promoter  
operably linked to a nucleotide sequence encoding at least one  
complementarity-determining region (CDR) or framework-  
determining region (FR) of monoclonal antibody 1F7, wherein said  
nucleotide sequence encodes the amino acid sequence shown in SEQ  
ID NO: 7 or SEQ ID NO: 24.

J.S. Serial No. 09/759,112  
Amendment dated December 29, 2003  
Response to Office Action of September 25, 2003

Claim 13 (previously presented): The vector of claim 12, wherein said nucleotide sequence encodes a variable heavy (VH) or variable light (VL) chain of monoclonal antibody 1F7.

Claim 14 (previously presented): The vector of claim 12, wherein said nucleotide sequence is operably linked to a human immunoglobulin constant region nucleotide sequence.

Claim 15 (previously presented): A cell line transformed with the vector of claim 12.

Claim 16 (withdrawn): A polypeptide expressed by the cell line of claim 15.

Claim 17 (withdrawn): A composition comprising the polypeptide of claim 16 and a pharmaceutically acceptable carrier.

Claim 18 (withdrawn): A method of modulating the immune response of a host infected with HIV comprising administering the polypeptide of claim 16 to the host.

U.S. Serial No. 09/759,112  
Amendment dated December 29, 2003  
Response to Office Action of September 25, 2003

Claim 19 (withdrawn): A method of modulating the immune response of a host infected with HIV comprising administering the polynucleotide of claim 1 to tissues of the host.

Claim 20 (withdrawn): A method of modulating the immune response of a host infected with HIV comprising administering the vector of claim 12 to the host.

Claim 21 (new): The vector of claim 12, wherein said nucleotide sequence is shown in SEQ ID NO: 5 or SEQ ID NO: 22.